Pharmacy Pearls: Lipid Management – Vascepa and Statin Intolerance

Pharmacy Pearls: Lipid Management – Vascepa and Statin Intolerance

February 5th, 2020 | Pharmacy Pearls

This edition of Pharmacy Pearls critically reviews the data of the REDUCE-IT trial for Vascepa, which resulted in its new FDA-labeled indication for cardiovascular risk reduction with mild hypertriglyceridemia. We have also included an algorithm for how to address statin-associated muscle symptoms (SAMS).

As always, we welcome any questions or feedback you may have.

Just email the Pharmacy Team.

PP Feb 2020 Vascepa and Statin Intolerance